JB Chemicals Share in Focus on Securing USFDA Approval for Hypertension Drug

JB Chemicals & Pharmaceuticals Ltd. has received approval from the United States Food and Drug Administration (USFDA) to manufacture and market Bisoprolol Tablets USP in 5 mg and 10 mg strengths. The approval was issued under the Abbreviated New Drug Application (ANDA) route.

As of 9:20 am on April 21, 2025, J B Chemicals and Pharmaceuticals share price was trading at ₹1,654.50, a 0.50% up, down 13.59% over the past six months and 7.88% over the past year.

Generic Version of Zebeta

The product is a generic version of Teva’s Zebeta tablets, which are prescribed for the management of hypertension. Bisoprolol is used to treat high blood pressure and belongs to the beta-blocker class of medications.

Product Details

  • Drug name: Bisoprolol Tablets USP
  • Strengths approved: 5 mg and 10 mg
  • Indication: Management of hypertension
  • Brand reference: Zebeta (Teva)

Approval Route

The approval comes through the ANDA process, which allows pharmaceutical companies to market a generic version of a previously approved drug, provided it meets regulatory requirements for safety, efficacy, and bioequivalence.

In a regulatory filing dated April 18, 2025, the company informed the National Stock Exchange of India that it had secured the approval. The announcement was signed by Sandeep Phadnis, Vice President – Secretarial and Company Secretary, JB Chemicals.

Geographic Market

The approval allows JB Chemicals to introduce the product in the United States, one of the largest pharmaceutical markets globally. The company did not provide additional commercial or launch-related details in the announcement.

Read More: KKR Expected to Sell Stake in JB Chemicals: Check Key Details Here

Conclusion

With this USFDA approval, JB Chemicals is cleared to supply Bisoprolol tablets in the US market. The drug will serve as an alternative to the branded version for the treatment of hypertension. No further information regarding timelines or sales projections was disclosed in the filing.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Government Confirms No GST on UPI Payments Over ₹2,000

The Ministry of Finance has officially denied media reports suggesting that the government is considering imposing Goods and Services Tax (GST) on UPI transactions over ₹2,000. In a statement released on April 18, the ministry said the claims are false and not backed by any current proposal or discussion.

No Proposal Under Consideration

According to the ministry, “there is no such proposal before the government.” GST is currently applied only to specific charges like the Merchant Discount Rate (MDR) applicable to certain payment instruments. However, in January 2020, MDR was removed from person-to-merchant (P2M) UPI transactions by a CBDT notification, and as a result, no GST applies to these transactions.

Government Incentive Scheme for UPI

To support UPI adoption, the government has been running an incentive scheme since FY 2021-22. This scheme aims to promote low-value P2M UPI transactions by covering some of the costs for merchants.

Annual incentive payouts under the scheme:

  • FY 2021-22: ₹1,389 crore
  • FY 2022-23: ₹2,210 crore
  • FY 2023-24: ₹3,631 crore

UPI Usage Growth

UPI transaction values have grown from ₹21.3 lakh crore in FY 2019-20 to ₹260.56 lakh crore by March 2025. Out of this, ₹59.3 lakh crore comes from P2M transactions, indicating increased use among businesses.

GST Collection Data

In March 2025, GST collections (after refunds) stood at ₹1.77 trillion, up 7.3% from the previous year. For FY25, GST revenue rose 8.6% year-on-year to ₹19.56 trillion. Net tax revenue from domestic sales increased 9.3% in March to ₹1.38 trillion.

Read More: GST on UPI Over ₹2,000? Here’s What You Need to Know

Conclusion

The government has confirmed that it is not planning to levy GST on UPI transactions above ₹2,000. No MDR is currently charged on such transactions, and UPI continues to be supported through incentives and policy measures.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

NFL to Acquire 18% Stake in Assam Urea Plant Joint Venture for ₹572.45 Crores

National Fertilizers Limited (NFL) will invest around ₹572.45 crore to acquire an 18% equity stake in a proposed joint venture company that will set up a new ammonia-urea plant in Namrup, Assam. The company’s board approved the proposal at its meeting held on April 18, 2025.

As of 9:20 AM on April 21, 2025, National Fertilizers share price was trading at ₹85.68, a 0.35% up, down 25.69% over the past six months and 16.63% over the past year.

Project Background

The joint venture aims to establish the Namrup-IV Fertilizer Plant within the existing premises of Brahmaputra Valley Fertilizer Corporation Ltd (BVFCL). The plant will have an annual urea production capacity of 12.7 lakh tonnes. It is being developed as a brownfield project.

Ownership Structure

The proposed shareholding in the joint venture is as follows:

  • Government of Assam – 40%
  • National Fertilizers Ltd – 18%
  • Oil India Ltd – 18%
  • Hindustan Urvarak & Rasayan Ltd – 13%
  • Brahmaputra Valley Fertilizer Corporation Ltd – 11%

BVFCL’s contribution will be in the form of tangible assets instead of cash.

Project Cost and Other Details 

The estimated total project cost is ₹10,601.40 crore. The funding structure will follow a 70:30 debt-equity ratio. NFL’s share of ₹572.45 crore will be a cash investment.

The tentative timeline for mechanical completion and commissioning of the plant is 48 months from the project’s start date. The joint venture company is yet to be formally incorporated. Once operational, the plant is expected to cater to urea demand in Assam, Bihar, West Bengal, Eastern Uttar Pradesh, and Jharkhand.

Read More: Best Fertilizer Stocks in India in April 2025 – 5Y CAGR Basis

Regulatory Approvals

The Union Cabinet approved the project in March 2025. It falls under the administrative control of the Department of Fertilizers, Ministry of Chemicals and Fertilizers.

Conclusion

The Namrup-IV project is in the early stages of formation. NFL’s board has approved its participation alongside other public sector and state government entities. The joint venture will proceed with incorporation and project execution over the next four years.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Zydus Lifesciences Arm Secures Global Rights to Brazil’s Braile Biomedica’s TAVI System

Zydus Medtech, a subsidiary of Zydus Lifesciences, has signed a global licensing agreement with Brazil-based Braile Biomedica to commercialise its Transcatheter Aortic Valve Implantation (TAVI) system. The deal covers markets in India, Europe, and other selected regions.

As of 9:24 am on April 21, 2025, Zydus Lifesciences share price was trading at ₹831.75, a 0.024% up, down 17.38% over the past six months and 13.42% over the past year.

Rights and Responsibilities

Under the agreement, Zydus Medtech will hold exclusive rights to market Braile Biomedica’s balloon-expandable TAVI system in the mentioned geographies. Braile will continue manufacturing the device in Brazil, while Zydus will manage marketing and regulatory operations. In some cases, Zydus will also produce specific components of the system.

Market Context

The global market for TAVI devices is currently valued at over USD 6 billion. Demand has grown steadily due to the increasing preference for less invasive cardiac procedures. The partnership allows Zydus Medtech to enter the structural heart therapy space, where the company is actively building its interventional cardiology portfolio.

Plans

A clinical research programme for the TAVI device is expected to start next year. In addition to the current system, the agreement includes plans for a pipeline of new products to be launched over the next three years.

Overview

Zydus Lifesciences employs more than 27,000 people worldwide, including over 1,400 researchers. Braile Biomedica has nearly five decades of experience in cardiovascular device development and operates across Latin America.

The TAVI system is a medical device used in minimally invasive procedures to treat aortic stenosis. It is particularly used for elderly patients or those considered high-risk for open-heart surgery. The system uses a valve constructed from a single sheet of bovine pericardium, which differs from the standard three-leaflet structure. This design was initially developed as part of a doctoral thesis by cardiac surgeon Dr. Domingo Braile.

Read More: Why Did Lupin and Zydus Share Price Decline Sharply?

Conclusion

The licensing deal enables Zydus Medtech to expand its offerings in the cardiovascular space while supporting the global distribution of Braile’s TAVI technology.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

SEBI Plans to Raise Mutual Fund Caps in REITs and InvITs

The Securities and Exchange Board of India (SEBI) has released a consultation paper proposing changes to investment limits for mutual funds in Real Estate Investment Trusts (REITs) and Infrastructure Investment Trusts (InvITs). The is aimed at expanding investment scope and adjusting current regulatory caps.

Existing and Proposed Limits

Under the existing framework, mutual funds can invest a maximum of 10% of a scheme’s Net Asset Value (NAV) in REITs and InvITs, with a limit of 5% per single issuer.

SEBI has proposed the following changes:

  • Single issuer limit: To be raised from 5% to 10% of the scheme’s NAV.
  • Overall exposure limit: To be increased from 10% to 20% for equity and hybrid schemes.
  • Debt schemes: To retain the existing 10% cap, citing the higher risk and perpetual nature of REITs and InvITs.

Current Exposure

As of December 31, 2024, mutual funds had invested ₹20,087 crore in REITs and InvITs. The average exposure across different types of schemes was:

  • Equity schemes: 2.1%
  • Debt schemes: 3.7%
  • Hybrid schemes: 2.4%

There are currently four REITs and 17 InvITs listed on Indian stock exchanges.

Market Classification and Liquidity

Globally, REITs and InvITs are included in major indices such as the MSCI India Small Cap Index and the FTSE India Index, and are typically classified as equity instruments. In India, however, they are still treated as hybrid instruments due to differences in structure, cash flow, and valuation.

SEBI has also asked for feedback on whether REITs and InvITs in India should be reclassified as equity instruments for index inclusion.

Read More: SEBI Proposes Key Reforms for Angel Funds to Boost Capital Flow to Start-Ups

Conclusion

SEBI’s proposal is under review and open to public and industry feedback. If implemented, the new limits could alter how mutual funds allocate investments in infrastructure and real estate-related instruments.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Aditya Birla Sun Life Declares Income Distribution Across Three Funds

Aditya Birla Sun Life Mutual Fund has declared income distribution under the Income Distribution cum Capital Withdrawal (IDCW) option for select schemes. The record date for all distributions is set as April 22, 2025.

Schemes and Distribution 

The income distribution is applicable to both regular and direct plans under three mutual fund schemes. Details are as follows:

Scheme(IDCW) IDCW (₹/unit)
Aditya Birla SL Arbitrage – Direct Plan 0.067
Aditya Birla SL Arbitrage – Regular Plan 0.065
Aditya Birla SL Balanced Advantage – Direct Plan 0.169
Aditya Birla SL Balanced Advantage – Regular Plan 0.149
Aditya Birla SL International Equity – Regular 1.052

 

Record Date

The record date for determining eligibility for the distribution is April 22, 2025. Unit holders whose names appear in the records as of this date will be entitled to receive the declared IDCW.

Scheme Overview

  • Aditya Birla SL Arbitrage Fund: Operates across equity and derivatives markets, aiming to capture price differentials. Both direct and regular plans have announced small payouts.
  • Aditya Birla SL Balanced Advantage Fund: Allocates assets dynamically between equity and debt. Both direct and regular plans have declared moderate income distributions.
  • Aditya Birla SL International Equity Fund: Focuses on global equities. The regular plan under this scheme has declared the highest distribution among the three.

Distribution Type

These are regular IDCW payouts and will be processed as per the standard guidelines of the fund house. Net Asset Values (NAVs) of the respective plans will be adjusted accordingly on the ex-distribution date.

Read More: Income Distribution Announced Across Mutual Fund Schemes

Conclusion

All income distribution amounts declared are on a per-unit basis. Investors can refer to the official documentation or consult their distributors for further operational details or updates related to the payout.

Ensure steady returns with systematic withdrawals! Estimate your withdrawals with our SWP Calculator and manage your finances seamlessly.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Mutual Fund investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Eternal(Zomato) Proposes 49.5% Cap on Foreign Ownership to Maintain IOCC Status

Eternal Limited (formerly Zomato Limited) has proposed a cap of up to 49.5% on total foreign ownership. The board approved this on April 18, 2025. Shareholders will vote on the resolution through electronic postal ballot from April 20 to May 19, 2025. The outcome will be announced by May 21.

As of 9:32  am on April 21, 2025,  Eternal share price was trading at ₹227.96, a 1.58% down. The shares are down 19.25% over the past six months and up 10.96% over the past year.

What the Cap Covers

The proposed ceiling applies to all foreign investments, including:

  • Foreign Direct Investment (FDI)
  • Foreign Portfolio Investment (FPI)
  • Indirect investments by NRIs
  • Investments by foreign-owned or controlled Indian entities

This limit includes all equity instruments as defined under FEMA – equity shares, compulsorily convertible preference shares, and debentures, whether acquired in the primary or secondary market. The only exclusion is investments through the non-repatriation route.

Reason for the Cap

As of March 31, 2025, around 55% of Eternal’s fully diluted shareholding was held domestically, with foreign ownership at approximately 45%. This qualifies the company as an Indian-Owned and Controlled Company (IOCC) under Indian foreign exchange regulations. Eternal does not have a promoter group, so this cap is being proposed to maintain IOCC status.

Quick Commerce Link

Eternal’s quick commerce unit, Blinkit, is currently structured as a third-party marketplace. With IOCC classification in place, the company plans to gradually shift to owning inventory directly. Blinkit saw 93% YoY growth in gross order value (GOV) in FY24, and 123% growth over the nine-month period ending December 2024.

Read More: Zomato to Trade as ‘Eternal’ on Stock Exchanges Starting April 9, 2025

Conclusion

If shareholders approve the proposal, the cap will be implemented in compliance with FEMA and SEBI regulations. Any change in the company’s future classification may lead to a review of this limit.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Divi’s Laboratories Share Price Gains on Apr 21; Signs Long-Term Supply Agreement

Divi’s Laboratories Ltd recently informed the stock exchanges that it has signed a long-term manufacturing and supply agreement with a global pharmaceutical company. The contract is international in scope and pertains to the supply of advanced intermediates.

Confidentiality Clause

The name of the customer and quantitative terms of the deal have not been disclosed due to a confidentiality agreement between the parties. Divi’s stated that the agreement is expected to contribute to its revenue over time, but specific figures were not shared.

The company confirmed that manufacturing under this agreement is scheduled to commence from January 2027.

Investment Plan

To support the execution of this contract and other capacity requirements, Divi’s Laboratories plans to invest between ₹650 crore and ₹700 crore in capacity addition at its manufacturing facilities. The investment will be funded through internal accruals.

There is no upfront payment involved as part of this agreement.

Nature and Scope

As per the company’s regulatory filing, the deal involves the manufacturing and supply of advanced intermediates. No related party transactions are involved in this agreement. The update was disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Share Performance

As of 9:30 AM on April 21, 2025, Divi’s Laboratories share price was trading at ₹5,857.50, a 3.86% up, 5.11% lower over the past six months, but up 50.42% over the past year. The 52-week high stands at ₹6,285, while the 52-week low is ₹3,641.

Conclusion

The agreement is part of Divi’s operations in the custom synthesis space. There is no upfront payment involved in this agreement. Further details remain undisclosed as per confidentiality terms.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Infosys to Acquire The Missing Link and MRE Consulting for Global Expansion

Infosys has approved the acquisition of two companies, MRE Consulting and The Missing Link, to support its international expansion. MRE Consulting is based in Houston, Texas, while The Missing Link operates out of Australia. Both companies provide technology services in areas like digital consulting, network integration, and cybersecurity.

As of 9:35 am on April 21, 2025, Infosys share price was trading at ₹1,445.40, a 1.82% up, and up 2.01% over the past week, but down 22.94% over the last six months.

About The Companies 

MRE Consulting is a US-based technology consultancy that works with enterprise clients, particularly in the energy and utilities sectors. Its services include cloud transformation, IT strategy, and systems integration.

The Missing Link provides cybersecurity and IT infrastructure solutions. Its services cover managed detection and response, security operations, automation, and network solutions.

Quarterly Results

Infosys reported a net profit of ₹7,033 crore for Q4 FY25, compared to an estimated ₹7,278 crore. Revenue for the quarter stood at ₹40,925 crore, a decline of 2% compared to the previous quarter. Constant currency revenue declined by 3.5%.

As per the report, the company expects revenue growth of 0–3% for FY26, lower than the earlier guidance of 4.5-5%. EBIT margin guidance remains unchanged at 20–22%. Additionally, Infosys recommended a final dividend of ₹22 per share for the financial year.

Additional Investment 

The Company also announced that Mitsubishi Heavy Industries will invest in HiPUS, a joint venture with Infosys in Japan. HiPUS delivers digital engineering and IT services. No further financial details were disclosed.

Conclusion

Infosys has announced the acquisitions of MRE Consulting and The Missing Link as part of its global business operations. These developments were shared along with the company’s Q4 financial results and updated guidance for the upcoming fiscal year.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

TATA IPL 2025: Mastering the Yorker – How to Tackle High Interest Debt Before It Hits You

In cricket, the yorker is one of the most lethal deliveries a bowler can bowl. It’s precise, it’s fast, and it targets the base of the stumps. A yorker often catches even the best batsmen off guard. If you’re not ready for it, it’s game over.

In the financial world, high-interest debt behaves a lot like a surprise yorker. It’s quick, unrelenting, and if misjudged, can uproot your entire financial game plan. Whether it’s credit card dues, personal loans, or high-leverage positions, failing to prepare for this financial yorker can result in serious damage to your wealth-building innings.

To counter this, you need a solid stance, quick footwork, and most importantly, the ability to anticipate.

Understanding the Financial Yorker: The Threat of High-Interest Debt

Think about a batsman facing a death-over specialist hurling in-swinging yorkers at 145 kmph. If he misjudges his footwork or delays his shot, the stumps will go flying in a flash.

Similarly, high-interest debt—especially when left unchecked—can corner even the most disciplined investors into a financial misfortune..

These financial yorkers come in various forms. It could be credit card rollovers with 35–45% annualised interest, or personal loans with inflexible EMIs.

But most critical of these are over-leveraged trading positions with compounding exposure. While an essential tool to size up your trading positions beyond your capital, over-leveraged positions can send your financial play into upheaval if things do not turn up as per your anticipation

When you’re saddled with financial yorkers, your earnings are diverted to repayments instead of compounding towards wealth. Just like a batsman losing his wicket to a surprise yorker, your financial growth is cut short.

Read the Pitch: Know Your Exposure with the Margin Calculator

A great batsman doesn’t just react; he anticipates based on real time circumstances. He studies the bowler’s grip, watches the run-up, and prepares for the yorker even before it’s bowled.

For an investor or trader, this level of preparation comes from understanding the cost of the transaction and your position—especially when using margin.

AngelOne’s Margin Calculator acts as your virtual pitch reader. It tells you exactly how much margin you need to maintain a trading position. Think of it as your front-foot defence against volatility. It gives clarity on:

  • Initial margin requirement
  • Available funds vs exposure
  • Leverage impact on your position
  • Risk if the trade goes against you

Instead of being surprised by sudden calls for funds or margin shortfalls, you step in with confidence, fully aware of the delivery you’re facing.

Read More:TATA IPL 2025: What Bowling Can Teach Us About Risk Management Strategies.

Quick Singles or Boundary Risk? Use Margin Trading Facility with Discipline

In the middle overs of a cricket match, smart batsmen rotate strike while occasionally stepping out for a big hit. The key lies in knowing when to accelerate and when to consolidate.

AngelOne’s Margin Trading Facility enables you to buy stocks by paying only a portion of the total value upfront. It’s the financial equivalent of stepping out to convert a good length ball into a scoring opportunity.

However, using MTF without a plan is like swinging blindly at a yorker. You might connect and score big, or you might get clean bowled. Here’s how to use it smartly:

  • Only leverage high-conviction trades. Just as you don’t advance down the track on every ball, don’t use margin for just any stock.
  • Set stop-losses. Prepare for the unexpected bounce or swing.
  • Track interest cost on borrowed capital. Margin comes at a price, and if the trade turns against you, the cost can pile up, just like high-interest debt.

When used correctly, MTF helps you play aggressively without exposing your stumps. It provides liquidity, increases flexibility, and helps seize market opportunities—without overextending your finances.

Train in the Nets: Use Simulators and Calculators Before Going Live

Cricketers spend hours in the nets preparing for yorkers with drills and simulations. Similarly, investors should practice financial discipline using available tools before putting real money at stake.

  • Use the Margin Calculator to simulate your position size.
  • Plan exit strategies before entering a trade.
  • Review MTF interest costs over different holding periods.

These preparations make sure you’re not stepping into the crease blindfolded. When the yorker comes—and it will—you’ll be ready with a dead bat or a well-timed flick to the fine leg.

Read More: TATA IPL 2025: Pitch Report: Analyzing Market Conditions Before Making Investment Decisions.

Winning the Yorker: Build a Resilient Financial Strategy

In T20s, the last five overs can decide the match. And in personal finance, how you handle debt, leverage, and risk in your 30s and 40s decides the kind of life you’ll lead in your 50s and beyond.

Use AngelOne tools like the Margin Calculator and MTF strategically. Know your risk, play with discipline, and don’t fall for the temptation of over-leveraging.

A well-played yorker doesn’t just save your wicket—it can turn the tide in your favour. Master the art, stay on your toes, and bat your way to a strong financial score. Because in cricket and in finance, it’s not just about power—it’s about precision under pressure.

Disclaimer: This blog has been written exclusively for educational purposes. http://bit.ly/usSGoH